Biochemical basis of type IB (E1beta ) mutations in maple syrup urine disease. A prevalent allele in patients from the Druze kindred in Israel.
Maple syrup urine disease (MSUD) is a metabolic disorder associated with often-fatal ketoacidosis, neurological derangement, and mental retardation. In this study, we identify and characterize two novel type IB MSUD mutations in Israeli patients, which affect the E1beta subunit in the decarboxylase (E1) component of the branched-chain alpha-ketoacid dehydrogenase complex. The recombinant mutant E1 carrying the prevalent S289L-beta (TCG --> TTG) mutation in the Druze kindred exists as a stable inactive alphabeta heterodimer. Based on the human E1 structure, the S289L-beta mutation disrupts the interactions between Ser-289-beta and Glu-290-beta', and between Arg-309-beta and Glu-290-beta', which are essential for native alpha(2)beta(2) heterotetrameric assembly. The R133P-beta (CGG --> CCG) mutation, on the other hand, is inefficiently expressed in Escherichia coli as heterotetramers in a temperature-dependent manner. The R133P-beta mutant E1 exhibits significant residual activity but is markedly less stable than the wild-type, as measured by thermal inactivation and free energy change of denaturation. The R133P-beta substitution abrogates the coordination of Arg-133-beta to Ala-95-beta, Glu-96-beta, and Ile-97-beta, which is important for strand-strand interactions and K(+) ion binding in the beta subunit. These findings provide new insights into folding and assembly of human E1 and will facilitate DNA-based diagnosis for MSUD in the Israeli population.
Wynn
R M
RM
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Chuang
J L
JL
Sansaricq
C
C
Mandel
H
H
Chuang
D T
DT
D042942:3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); D000483:Alleles; D001120:Arginine / Q000737:chemistry; D015153:Blotting, Western; D002460:Cell Line; D002648:Child; D002675:Child, Preschool; D002850:Chromatography, Gel; D019281:Dimerization; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli / Q000378:metabolism; D005192:Family Health; D005260:Female; D018698:Glutamic Acid / Q000737:chemistry; D019791:Guanidine / Q000494:pharmacology; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007557:Israel; D007658:Ketone Oxidoreductases / Q000737:chemistry* / Q000235:genetics*; D007700:Kinetics; D008297:Male; D008375:Maple Syrup Urine Disease / Q000235:genetics*; D008958:Models, Molecular; D009097:Multienzyme Complexes / Q000737:chemistry* / Q000235:genetics*; D009154:Mutation; D010957:Plasmids / Q000378:metabolism; D011485:Protein Binding; D017422:Sequence Analysis, DNA; D012694:Serine / Q000737:chemistry; D013696:Temperature; D013997:Time Factors
D009097:Multienzyme Complexes; D018698:Glutamic Acid; D012694:Serine; D001120:Arginine; D007658:Ketone Oxidoreductases; D042942:3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); D019791:Guanidine